Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Euro Surveill ; 26(23)2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-34114540

RESUMO

We describe four secondary fungal infections caused by Mucorales species in COVID-19 patients. Three COVID-19 associated mucormycosis (CAM) occurred in ICU, one outside ICU. All were men aged > 50 years, three died. Clinical presentations included pulmonary, rhino-orbital cerebral and disseminated infection. Infections occurred in patients with and without diabetes mellitus. CAM is an emerging disease and our observations underscore the need to be aware of invasive mucormycosis, including in COVID-19 patients without (poorly controlled) diabetes mellitus and outside ICU.


Assuntos
COVID-19 , Mucorales , Mucormicose , Feminino , Humanos , Masculino , Mucormicose/diagnóstico , Países Baixos/epidemiologia , SARS-CoV-2
2.
Am J Transplant ; 20(7): 1896-1901, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32337790

RESUMO

The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.


Assuntos
Infecções por Coronavirus/complicações , Infecções por Coronavirus/terapia , Everolimo/farmacocinética , Falência Renal Crônica/complicações , Transplante de Rim , Pneumonia Viral/complicações , Pneumonia Viral/terapia , Transplantados , Adulto , Antivirais/administração & dosagem , Antivirais/farmacocinética , Betacoronavirus , COVID-19 , Cloroquina/administração & dosagem , Cloroquina/farmacocinética , Combinação de Medicamentos , Interações Medicamentosas , Everolimo/administração & dosagem , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/administração & dosagem , Imunossupressores/farmacocinética , Falência Renal Crônica/cirurgia , Lopinavir/administração & dosagem , Lopinavir/farmacocinética , Masculino , Países Baixos , Pandemias , Radiografia Torácica , Ritonavir/administração & dosagem , Ritonavir/farmacocinética , SARS-CoV-2 , Resultado do Tratamento
3.
J Invasive Cardiol ; 36(1)2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38224298

RESUMO

A 54-year-old woman was referred for veno-venous extracorporeal oxygenation membrane (VV-ECMO) due to refractory hypoxic respiratory failure caused by COVID-19, despite mechanical ventilation and prolonged prone positioning.


Assuntos
COVID-19 , Oxigenação por Membrana Extracorpórea , Feminino , Humanos , Pessoa de Meia-Idade , Decúbito Ventral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA